EUVIMEDEUVIMED entdecken
Crossref

Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas

Jingzhe Xiang iD, Jixue Hou, Hao Zhang

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-25-0373 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Jingzhe Xiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, PR China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Adenocarcinoma, Follicular, Adenoma, Oxyphilic. Die Arbeit nennt 68 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular thyroid carcinoma (FTC) and oncocytic thyroid carcinoma (OTC) are distinct entities with differing biological behaviors, yet optimal surgical and radioactive iodine (RAI) therapy management remains debated. Demographic, clinicopathological, and treatment characteristics were gathered from the Surveillance, Epidemiology, and End Results (SEER) database and compared between FTC and OTC according to tumor size. The Kaplan–Meier method and log-rank test were used to analyze cancer-specific survival (CSS). The effect of potential predictors associated with survival was estimated using the Cox regression model. 13,653 patients were included in our study. OTC patients were older and presented higher rates of extrathyroidal extension (ETE) and lymph node metastases (LNM), while FTC had higher distant metastasis (DM) rates. Increasing tumor size was correlated with worse features in both subtypes. Total thyroidectomy (TT) had no CSS benefit over less than TT (LTT) for FTC ≤2 cm or any OTC size group. TT was paradoxically associated with worse CSS for FTC >2 cm. RAI therapy did not improve CSS for patients with ETE (FTC or OTC) or DM (OTC). Multivariable analysis confirmed that TT was independently associated with worse CSS in FTC but not in OTC, while RAI therapy was beneficial in FTC but not in OTC. FTC and OTC exhibited distinct clinical behaviors. In conclusion, TT did not improve CSS for small FTC (≤2 cm) or any OTC, and appeared to be associated with worse outcomes in larger FTC. RAI therapy provided limited benefit in OTC, especially with DM. Treatment should be individualized, avoiding routine aggressive surgery or RAI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsAdenocarcinoma, FollicularAdenoma, OxyphilicHumansFemaleMaleMiddle AgedThyroidectomyAdultAgedIodine Radioisotopes

Stichwörter der Autor:innen

follicular thyroid carcinomaoncocytic thyroid carcinomaradioactive iodinesurgery

Substanzen

Iodine Radioisotopes

Autor:innen und Institutionen

  • Department of Thyroid Surgery, The First Hospital of China Medical University, Shenyang, PR China.
  • Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Shihezi University, Shihezi, PRChina.

ORCID-Profile: Jingzhe Xiang

Zitieren

APA

Xiang, J., Hou, J., & Zhang, H. (2025). Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas. Endocrine-Related Cancer. https://doi.org/10.1530/erc-25-0373

Vancouver

Xiang J, Hou J, Zhang H. Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas. Endocrine-Related Cancer. 2025. doi:10.1530/erc-25-0373

BibTeX
@article{Xiang2025,
  author = {Xiang, Jingzhe and Hou, Jixue and Zhang, Hao},
  title = {Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-25-0373}
}
Kostenlos starten →